These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3126410)

  • 21. Low and variable presence of valproic acid in human brain.
    Shen DD; Ojemann GA; Rapport RL; Dills RL; Friel PN; Levy RH
    Neurology; 1992 Mar; 42(3 Pt 1):582-5. PubMed ID: 1549218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
    Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
    J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of different doses of valproic acid on the serum levels of total and free diphenylhydantoin.
    Alvarez N
    Clin Electroencephalogr; 1985 Apr; 16(2):104-10. PubMed ID: 3924446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacokinetic study to determine the drug interaction between valproate and propranolol.
    Nemire RE; Toledo CA; Ramsay RE
    Pharmacotherapy; 1996; 16(6):1059-62. PubMed ID: 8947979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circadian variation of Valproic acid pharmacokinetics in mice.
    Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
    Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
    Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
    Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development.
    Ueshima S; Aiba T; Sato T; Matsunaga H; Kurosaki Y; Ohtsuka Y; Sendo T
    Biol Pharm Bull; 2011; 34(1):108-13. PubMed ID: 21212527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valproic acid monotherapy induces DNA oxidative damage.
    Schulpis KH; Lazaropoulou C; Regoutas S; Karikas GA; Margeli A; Tsakiris S; Papassotiriou I
    Toxicology; 2006 Jan; 217(2-3):228-32. PubMed ID: 16289809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
    Fattore C; Messina S; Battino D; Croci D; Mamoli D; Perucca E
    Epilepsy Res; 2006 Aug; 70(2-3):153-60. PubMed ID: 16730950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatal hyperammonemia in a patient with systemic lupus erythematosus.
    Ichikawa H; Amano T; Kawabata K; Kushiro M; Wada J; Nagake Y; Makino H
    Intern Med; 1998 Aug; 37(8):700-3. PubMed ID: 9745859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sodium valproate: a hyperammonemic drug. Study in the epileptic and healthy volunteer].
    Marescaux C; Warter JM; Laroye M; Rumbach L; Micheletti G; Koehl C; Imler M; Kurtz D
    J Neurol Sci; 1983 Feb; 58(2):195-209. PubMed ID: 6403673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.
    Battino D; Estienne M; Avanzini G
    Clin Pharmacokinet; 1995 Oct; 29(4):257-86. PubMed ID: 8549027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures.
    Redenbaugh JE; Sato S; Penry JK; Dreifuss FE; Kupferberg HJ
    Neurology; 1980 Jan; 30(1):1-6. PubMed ID: 6985719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutritional influence on serum ammonia in young patients receiving sodium valproate.
    Laub MC
    Epilepsia; 1986; 27(1):55-9. PubMed ID: 3081337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy.
    Cloyd JC; Kriel RL; Fischer JH; Sawchuk RJ; Eggerth RM
    Neurology; 1983 Feb; 33(2):185-91. PubMed ID: 6401848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valproic acid clearance in children with epilepsy.
    Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
    J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.